Why MEDDDICAL
The RWE landscape is crowded.
Independent guidance is rare.
Most organisations navigating real-world evidence have no shortage of vendors willing to help. What they lack is an advisor with no data to sell and no vendor to represent — who can tell them honestly which partnership serves their specific requirements and which does not.
The independence question
We are not a data vendor. We are not a CRO. We do not represent any provider.
The real-world data market has grown into a landscape of dozens of overlapping providers — each with genuine strengths in some areas and material gaps in others. Navigating it requires someone who has evaluated those providers independently and has no commercial incentive to steer you toward any of them.
MEDDDICAL connects qualified pharmaceutical and MedTech organisations with appropriate health insurance data access partners. We handle the strategic evaluation, the requirements definition, the compliance navigation, and the use-case alignment. When an engagement is complete, the data partnership you have entered is the right one for your evidence requirements — not the one that generated the highest referral fee.
That distinction matters more than it might appear. The cost of a misaligned data partnership — in wasted budget, failed submissions, and delayed evidence generation — consistently exceeds the cost of independent advisory support many times over.
“The challenge most organisations face is not finding data providers. It is determining which combination of capabilities aligns with their strategic priorities.”
MEDDDICAL Advisory Position
What we bring
Four capabilities that determine whether a real-world evidence programme succeeds or stalls
1. Compliant & Secure by Design
We guide you toward data partnerships built on GDPR-compliant, aggregated or synthetic data architectures — so you gain actionable insights without compromising patient privacy or regulatory standing. Every recommendation is evaluated against the compliance requirements of your specific use case and geographic markets before it reaches you.
2. Faster Time to Insight
The data vendor evaluation process — if conducted without prior expertise — typically takes three to six months and still produces suboptimal outcomes. Expert advisory support that matches your requirements to pre-structured, analysis-ready data sources from the outset compresses that timeline substantially and eliminates the most common and expensive selection errors.
3. Deep RWE Landscape Expertise
The claims data landscape spans dozens of providers with overlapping but meaningfully distinct capabilities across coverage breadth, data recency, therapeutic area depth, linkage quality, and analytical sophistication. We bring evaluated familiarity with that landscape — including where each provider’s capabilities genuinely end and where their marketing begins.
4. Evidence Strategy Before Data Selection
The most consequential mistake in real-world evidence programmes is selecting a data source before the evidence question is clearly defined. We reverse that sequence — starting from the regulatory context, the payer requirement, or the clinical development question, and working backwards to the data source and study design that can credibly answer it.
What we are not:
Conflicts of interest that MEDDDICAL does not have
- ✕ A data vendor
We do not own or sell health data. Every data partnership recommendation we make is evaluated solely on fit for your requirements.
- ✕ A CRO with a preferred supplier list
We do not have commercial agreements with data providers that would incentivise us to steer you toward specific vendors regardless of fit.
- ✕ A consultancy that bills by the hour for generic advice
Our engagement model is structured around your specific evidence requirements — not around maximising billable time on activities that don’t advance your programme.
- ✕ A software platform that needs you to adopt its tools
We are tool-agnostic. Our recommendations are based on what serves your evidence strategy, not on what integrates with a proprietary platform we need you to license.
What we are
The advisory model that fills the gap
- ✓ An independent strategic advisor
We evaluate the RWD landscape on your behalf and tell you honestly what fits your requirements and what does not.
- ✓ A requirements definition partner
We work with you to define the evidence question, the regulatory or payer context, and the data and methodological requirements before any vendor conversation begins.
- ✓ A compliance navigation resource
We understand the GDPR, HIPAA, and regulatory compliance requirements that govern health data procurement across Continental European and global markets.
- ✓ A connector to the right data partnerships
Once requirements are defined and vendor options are evaluated, we connect your organisation with the data partner whose capabilities genuinely match your specific evidence programme.
Who works with us
The teams that benefit most from independent RWE advisory support
Market Access
Heads of Market Access navigating payer evidence requirements
Building the real-world comparative effectiveness evidence that HTA bodies and payers require — without an internal HEOR function large enough to do it independently.
Clinical Development
Clinical Development Directors evaluating external control arm feasibility
Assessing whether synthetic control arms, natural history studies, or externally controlled trial designs are viable and regulatory-acceptable for a current programme.
Regulatory Affairs
Regulatory Affairs leads structuring RWE submissions
Understanding what FDA and EMA now accept as real-world evidence for label expansions, post-market commitments, and supplemental indications — and how to document it credibly.
Commercial Analytics
Commercial Analytics teams building competitive intelligence
Accessing claims-based treatment pattern data, real-world market share analytics, and prescribing shift intelligence without building internal data infrastructure from scratch.
Lean Pharma & Biotech
Small and mid-size pharma teams without a dedicated RWE function
Building a credible real-world evidence programme without a ten-person internal team — using expert advisory support in place of the internal infrastructure they cannot yet afford to build.
Rare Disease
Rare disease sponsors navigating thin data environments
Identifying the specialist data partnerships — patient registries, linked EHR sources, synthetic augmentation — that can support synthetic control arm construction and natural history characterisation in small patient populations.
How we work
The advisory process from first conversation to data partnership
1. Define the evidence question
Every engagement starts with the same question: what specific decision does this evidence need to inform? Before any data source is evaluated, the regulatory context, payer requirement, or clinical development question is precisely defined — along with the methodological and compliance requirements that flow from it. This is the step that most teams skip, and it is the most expensive mistake in RWE programme design.
2. Evaluate the data landscape
With requirements clearly defined, we evaluate the available data sources against your specific use case — coverage breadth, therapeutic area depth, data recency, linkage quality, GDPR compliance architecture, and validation documentation. This evaluation draws on direct familiarity with the Pan-European and global RWD vendor landscape rather than on the vendors’ own marketing materials.
3. Navigate the internal approval process
Identifying the right data partner is only part of the challenge. Getting legal, compliance, IT, and finance to approve the engagement is frequently the larger blocker. We help you anticipate and address each stakeholder’s requirements — preparing the compliance documentation, the business case, and the vendor evaluation framework that accelerates internal approval from months to weeks.
4. Connect with the right data partnership
Once the requirements are defined, the data landscape is evaluated, and the internal approval process is prepared, we connect your organisation with the data partner whose capabilities genuinely match your evidence programme. The engagement ends with a data partnership that was selected for the right reasons — and a clear understanding of what it can and cannot deliver.
Further reading
Understand the landscape before entering any vendor conversation
RWD Medical
Real-World & Synthetic Healthcare Data for Pharma
The foundational guide to what real-world data is, what synthetic data adds, and how to evaluate data sources for your specific use case.
RWE Strategy
Real-World Evidence Strategy & Analytics
How to build a credible RWE programme — from evidence question definition through study design, data source selection, and regulatory submission.
Data Quality
Analysis-Ready RWE & Healthcare Data
Why the data engineering bottleneck costs more than the data itself — and how analysis-ready datasets eliminate it.
Methodology
Phenotype Validation in Claims Data
The RWE step that determines whether your disease cohort accurately represents the population your evidence is meant to reflect.
Data Sources
Health Insurance Datasets for Pharma
Continental European statutory health insurance claims data — what it covers, what it does not, and how to evaluate it for your specific indication.
Get Started
Discuss Your Evidence Requirements
The advisory conversation that defines requirements before any vendor or data commitment is made — at no cost to you.
Start here
The advisory conversation costs nothing. Getting the data selection wrong costs considerably more.
If you are navigating a real-world evidence requirement — for a regulatory submission, a payer negotiation, a competitive intelligence programme, or a clinical development decision — the conversation that defines your requirements before any vendor engagement begins is where we add the most value.